ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1953

Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019

CLAUDIA MENDOZA PINTO1, Pamela Munguía-Realpozo1, Ivet Etchegaray-Morales2, Mario García-Carrasco2, Paulina Cortés-Hernández1, Roberto Arreguín-Reyes1, Jorge Ayón-Aguilar1 and Gabriel Rodríguez-Castillo2, 1Instituto Mexicano del Seguro Socia, Puebla, Mexico, 2Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

Meeting: ACR Convergence 2023

Keywords: Mortality, Myopathies, population studies

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with polymyositis and dermatomyositis (PM/DM) present multiple complications that may lead to increased mortality rates and data on PM/DM mortality in Mexico is lacking.
The objective of this study was to assess mortality trends in PM/DM idiopathic inflammatory myopathies (IMM) in Mexico between 2000 and 2019, overall and by sex, age group, and geographic regions.

Methods: Data were acquired from the General Board of Health Information Open Access databases, and we identified deaths for PM/DM (ICD codes, 10th edition), which were recorded from 2000 to 2019 from all public hospitals nationwide. Age-standardized mortality rates (ASMR) per 100,000 persons were calculated for PM/DM and non-PM/DM overall, by sexes, and by geographic region. Annual percentage change (APC) and average annual percentage change (AAPC) in ASMR were calculated using Joinpoint regression software.

Results: We found 1,456 deaths from PM/DM and 11,343,652 non-PM/DM in Mexico from 2000 and 2019. The ASMR (per 100,000 inhabitants) was 0.07 over the period. The gender distribution of PM/DM deaths was 69.8% in women and 30.2% in men. Compared to non-PM/DM, PM/DM individuals had a higher proportion in the younger population (younger than 45 years) (40.2% vs. 22.3%). Overall, a significantly downtrend in the ASMR was identified from 2007 to 2017 in subjects with PM/DM (APC -3.2%; 95% CI, -5.3 to -1.0; p = 0.008), while mortality trends were stable for non-PM/DM individuals. Similar trends were identified by sex in PM/DM patients (Fig 1). The Joinpoint analysis did not identify variation in temporal trends in mortality rates by geographic region; however, an increment in the proportion of deaths in the ratio of PM/DM to non-PM/DM ASMR from 2000 to 2019 was detected in the Northern and Southern regions (+17.6% and +84.9%, respectively).

Conclusion: Over a 20-year period, we observed that deaths due to PM/DM occurred predominantly in females. A notable decrease in overall mortality rates was identified between 2007 and 2017. Differences by sex, age, and geographic region were also detected.

Supporting image 1

Temporal trends in age-standardized mortality in PM/DM subjects by sex.


Disclosures: C. MENDOZA PINTO: None; P. Munguía-Realpozo: None; I. Etchegaray-Morales: None; M. García-Carrasco: None; P. Cortés-Hernández: None; R. Arreguín-Reyes: None; J. Ayón-Aguilar: None; G. Rodríguez-Castillo: None.

To cite this abstract in AMA style:

MENDOZA PINTO C, Munguía-Realpozo P, Etchegaray-Morales I, García-Carrasco M, Cortés-Hernández P, Arreguín-Reyes R, Ayón-Aguilar J, Rodríguez-Castillo G. Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019 [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/mortality-trends-in-polymyositis-and-dermatomyositis-in-mexico-a-general-population-based-study-from-2000-to-2019/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-trends-in-polymyositis-and-dermatomyositis-in-mexico-a-general-population-based-study-from-2000-to-2019/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology